May 13th 2025
The proposed $700 million, 700,000-square-foot space will support the companies’ future joint portfolio of next-generation obesity medicines.
The evolution of therapeutic modalities drives the adoption of single-use technologies.
Industry Expert Q&A with David A. Steil
February 22nd 2016Q&A with David A. Steil, pharmaceutical market manager, Camfil Air Pollution ControlPharmTech: Recently there has been an emphasis on green and sustainable technology in the pharmaceutical/biopharmaceutical industries. In what ways does Camfil APC’s technology contribute to sustainability?